关于《代谢功能障碍相关纤维化5（MAF-5）评分预测代谢功能障碍普通人群的肝纤维化风险及预后》的评论 - Suppr | 超能文献

Comments on "Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction".

作者信息

Guan Yuting, Yang Jiaming, Xu Zudong

机构信息

Department of Gastroenterology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China.

Guangxi Medical University, Nanning, Guangxi, China.

出版信息

Gastroenterology. 2024 Dec;167(7):1504-1505. doi: 10.1053/j.gastro.2024.07.043. Epub 2024 Sep 7.

DOI:10.1053/j.gastro.2024.07.043

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Comments on "Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction".关于《代谢功能障碍相关纤维化5（MAF-5）评分预测代谢功能障碍普通人群的肝纤维化风险及预后》的评论

Gastroenterology. 2024 Dec;167(7):1504-1505. doi: 10.1053/j.gastro.2024.07.043. Epub 2024 Sep 7.

2

Metabolic Dysfunction-Associated Fibrosis 5 (MAF-5) Score Predicts Liver Fibrosis Risk and Outcome in the General Population With Metabolic Dysfunction.代谢相关脂肪性肝病-5（MAF-5）评分预测代谢相关脂肪性肝病患者的肝脏纤维化风险和结局。

Gastroenterology. 2024 Jul;167(2):357-367.e9. doi: 10.1053/j.gastro.2024.03.017. Epub 2024 Mar 19.

3

In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver fibrosis (AUC range, 0.73 to 0.81).在代谢功能障碍的成年人中，MAF-5 评分预测了肝纤维化的风险（AUC 范围为 0.73 至 0.81）。

Ann Intern Med. 2024 Oct;177(10):JC119. doi: 10.7326/ANNALS-24-02090-JC. Epub 2024 Oct 1.

4

A metabolome-derived score predicts metabolic dysfunction-associated steatohepatitis and mortality from liver disease.代谢组衍生评分可预测代谢功能障碍相关脂肪性肝炎及肝病死亡率。

J Hepatol. 2025 May;82(5):781-793. doi: 10.1016/j.jhep.2024.10.015. Epub 2024 Oct 16.

5

Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.低至中度饮酒与代谢功能障碍相关脂肪性肝病患者的纤维化增加有关。

J Hepatol. 2024 Dec;81(6):930-940. doi: 10.1016/j.jhep.2024.06.036. Epub 2024 Jul 4.

6

Noninvasive Hepatic Steatosis and Fibrosis Indices Differentially Predict Mortality in the Adult Korean Population.非侵入性肝脂肪变性和纤维化指标对韩国成年人群的死亡率具有不同的预测作用。

Clin Gastroenterol Hepatol. 2025 Jul;23(8):1366-1376. doi: 10.1016/j.cgh.2024.10.006. Epub 2024 Oct 26.

7

Correlation Between Coronavirus Disease 2019 Severity and Noninvasive Assessment of Liver Fibrosis in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease.2019 年冠状病毒病严重程度与代谢相关脂肪性肝病患者肝纤维化无创评估的相关性。

Turk J Gastroenterol. 2023 Dec;34(12):1227-1234. doi: 10.5152/tjg.2023.23004.

8

A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.用于检测代谢功能障碍相关脂肪性肝病患者显著纤维化的非侵入性检测组合并不优于单独使用磁共振弹性成像。

Eur Radiol. 2024 Jun;34(6):3882-3888. doi: 10.1007/s00330-023-10441-5. Epub 2023 Nov 21.

9

Fibrosis-4 Index Score Predicts Concomitant Coronary Artery Diseases Across the Spectrum of Fatty Liver Disease.纤维化 4 指数评分可预测脂肪性肝病各谱中并存的冠状动脉疾病。

Dig Dis Sci. 2023 Sep;68(9):3765-3773. doi: 10.1007/s10620-023-07987-1. Epub 2023 Jul 1.

10

Derivation and validation of the BIMAST score for predicting the presence of fibrosis due to Metabolic dysfunction-associated steatotic liver disease among diabetic patients in the community.基于社区中糖尿病患者代谢相关脂肪性肝病导致的纤维化存在情况，BIMAST 评分的推导和验证。

PLoS One. 2024 Sep 27;19(9):e0307500. doi: 10.1371/journal.pone.0307500. eCollection 2024.

引用本文的文献

1

The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies.脂肪肝疾病的肝细胞模型：从当前的影像诊断到创新的蛋白质组学技术

Front Med (Lausanne). 2025 Mar 5;12:1513598. doi: 10.3389/fmed.2025.1513598. eCollection 2025.